drugset / Trial / NCT00004816
A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis
Phase 1
Completed
25 enrolled
National Center for Research Resources (NCRR)
Stanford University · collab
Open-labelTreatment
Summary
OBJECTIVES: I. Evaluate the safety and immunogenicity of single and multiple doses of M-T412, a chimeric murine-human anti-CD4 monoclonal antibody, in patients with multiple sclerosis. II. Evaluate the pharmacokinetics of M-T412. III. Obtain preliminary data on the clinical response to M-T412.
Timeline
- Start
- 1995-07
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRILIXIMAB | Monoclonal antibody | — | Intravenous |